Esaote North America the addition of a new dedicated veterinary ultrasound product available for purchase in the USA, the MyLab™X75VET ultrasound system.
Partnership HealthPlan of California (PHC) said a new partnership with Gatekeeper Innovation Inc., the maker of Safer Lock prescription locking devices.
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™.
Epitome Risk said that its at-home neutralizing antibody test is now sold online. "Last week President Biden said U.S. health officials are considering Covid booster shots at five months," said Lisa Wilson, CEO of Epitome Risk.
Insilico Medicine, a global company specializing in the applications of the next-generation machine learning technologies for drug discovery and development, that its AI-powered drug discovery platform had delivered the preclinical candidate ("PCC") for kidney fibrosis.
ParaPRO, a specialty pharmaceutical company focused on innovative anti-parasitic treatments, the availability of Natroba™ (spinosad) Topical Suspension, 0.9%, the first product (new drug application) for scabies to be approved by the U.S.
AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announced today that it has entered into an agreement to acquire 80% of the equity interests of Weihai Hengyu Medical Products Co., Ltd., a leading Chinese manufacturer of elastomeric and plastic components used in injectable drug delivery.
RefleXion Medical, Inc., a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality that will one day treat all stages of cancer, today announced the sale of its RefleXion™ X1.
Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device for patients with non-valvular atrial fibrillation (NVAF).
Cellares Corporation, a life sciences technology company pioneering a revolutionary automated approach to cell therapy manufacturing, today announced that Poseida Therapeutics.